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Increased postmenopausal bone turnover leads to bone loss and fragility fracture risk. In the absence of osteoporosis, risk preventive measures,
particularly those modifying nutritional lifestyle, are appropriate. We tested the hypothesis that milk supplementation affects bone turnover related
to biochemical markers in a direction that, in the long term, may be expected to reduce postmenopausal bone loss. Thirty healthy postmenopausal
women aged 59·3 (SD 3·3) years were enrolled in a prospective crossover trial of 16 weeks. After a 4-week period of adaptation with diet providing
600 mg calcium plus 300 mg ingested as 250 ml semi-skimmed milk, participants were maintained during 6 weeks under the same 600 mg calcium
diet and randomized to receive either 500 ml semi-skimmed milk, thus providing a total of 1200 mg calcium, or no milk supplement. In the next 6
weeks they were switched to the alternative regimen. At the end of the each period, i.e. after 4, 10 and 16 weeks, blood and urinary samples were
collected. The changes in blood variables between the periods of 6 weeks without and with milk supplementation were: for parathyroid hormone,
23·2 pg/ml (P¼0·0054); for crosslinked telopeptide of type I collagen, 2624 pg/ml (P,0·0001); for propeptide of type I procollagen, 25·5 ng/ml
(P¼0·0092); for osteocalcin, 22·8 ng/ml (P¼0·0014). In conclusion, a 6-week period of milk supplementation induced a decrease in several
biochemical variables compatible with diminished bone turnover mediated by reduction in parathyroid hormone secretion. This nutritional
approach to postmenopausal alteration in bone metabolism may be a valuable measure in the primary prevention of osteoporosis.
Menopause: Milk supplementation: Calcium intake: Bone turnover
Increased bone turnover after menopause is considered a key
mechanism in bone loss and increased risk of fragility frac-
ture(1,2). In the general population pharmaceutical interven-
tion aimed at preventing bone loss is no longer widely
recommended within the 10-year period following meno-
pause. The reasons for this conservative attitude adopted by
the medical community stem from both cost-effectiveness
analysis and long-term safety of pharmaceutical intervention
on skeletal and extra-skeletal functions(3 – 6). Particularly,
the widespread use of hormone replacement therapy has
been reconsidered based on the assessment of benefits and
harm(7). Although considerable controversy surrounds the
use of hormone replacement therapy(8 – 11), the results of the
Women Health Initiative study(12) led to substantial modifi-
cations by health care providers in the prescription pattern
for the primary prevention of osteoporosis, with rapid
reduction in hormone replacement therapy use(13 – 15). Thus
what was considered as the best therapeutic approach in
the primary prevention of postmenopausal osteoporosis was
widely discontinued as documented by a 57 % prescription
reduction in the USA between 2002 and 2004(15). Therefore,
it appears timely to reconsider other preventive measures,
particularly by exploring strategies aimed at reasonably
modifying lifestyle factors that are known to exert a bene-
ficial impact on bone metabolism, such as nutrition and
physical activity. Several randomized controlled trials indi-
cate that calcium supplementation associated with a sufficient
vitamin D supply reduces postmenopausal or age-related
bone loss and fragility fracture(16 – 21). As for any chronic
therapies the effectiveness of pharmaceutical medication
can be compromised by poor adherence and/or persistence.
Insufficient compliance can be explained by various reasons
such as safety concerns, inconvenience of treatment schedule,
lack of motivation, and/or drug-related side-effects(22). Low
compliance holds true not only for specific anti-osteoporosis
drugs such as bisphosphonates or raloxifene, but also for
pharmaceutical preparations of calcium salts(22,23). In fact,
treatment compliance was particularly poor for calcium ^
vitamin D supplements(22). Furthermore, in a recent review
some clinical guidance was given regarding the use of cal-
cium and vitamin D for the prevention of fragility fracture
in the subjects at risk(24). The authors considered that calcium
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and vitamin D supplements remain medicinal products that
have to be prescribed by physicians and other health care
providers(24). In subjects without impending risk of osteo-
porosis, as for instance in postmenopausal women at 5–10
years from the time of menstruation cessation with no par-
ticular risk factor for osteoporosis, it appears advantageous
to provide calcium by increasing its dietary intake(24).
Dairy products have a relatively high calcium content as
compared to other usual foods. Furthermore, dairy products
also provide protein that is certainly an essential nutrient
for bone health(25 – 28).
The most relevant end-point to demonstrate the efficiency
of an intervention in the context of osteoporosis is the
prospective recording of fragility fractures. This is an
extremely demanding end-point that requires enrolment of
several thousands of subjects associated with very long-
term follow-up, particularly in the absence of prevalent
osteoporosis.
Changes in bone biochemical markers have been shown to
predict not only the rate of bone loss, but also the risk of inci-
dent fragility fractures(29 – 34). The early predictive effect of
bone turnover inhibition of an intervention reducing hip,
non-spine and vertebral fracture appears to be at least as
strong as that observed with change in areal bone mineral den-
sity (aBMD)(34). Furthermore, this predictive value of bone
marker variation on bone loss in postmenopausal women
was documented not only with bisphosphonate treatment(32,34)
but also with calcium supplementation(33). Note that the mag-
nitude ot the early response of bone remodelling biochemical
markers is not tightly related to the degree of fracture risk
reduction(30 – 33).
In the present study we investigated in a group of healthy
postmenopausal women, with mean age of 59·5 years, display-
ing a rather moderate reduction in aBMD as compared to
young adult subjects, whether milk supplementation would
influence biochemical markers in a way compatible with a
reduction in bone turnover.
Materials and methods
Participants
Thirty healthy women aged between 55 and 65 years, 5
years or more since menopause, volunteered for being
enrolled into a prospective crossover trial of 16 weeks. Per-
sonal history and clinical examination warranted that those
enrolled did not suffer from any disease and/or were not
under medical therapy. None of them had taken hormonal-
related therapy for the prevention of postmenopausal dis-
orders during the last 12 months preceding the entry into
the trial; no calcium supplementation; neither antiosteoporo-
tic medication including bisphosphonates, calcitonin, raloxi-
fene, strontium ranelate, vitamin D derivatives, nor
medication suggested to act on bone metabolism such as
tibolone, anabolic steroids, dehydroepiandrostereone, iprifla-
vone and other phytoestrogens, or statins. Inclusion criteria
were: BMI ranging between 20 and 27 kg/m2; plasma con-
centration of follicle-stimulating hormone above 20 IU/l;
absence of osteoporosis as defined by osteodensitometric
T-score value of #22·5(35), or history of low trauma frac-
ture; absence of milk distaste, intolerance or allergy to
cows’ milk or other dairy products; stable food consumption
habits in the last 3 months; mean spontaneous calcium
intake $ 600 mg/d, with no more than 400 mg provided by
non-dairy products such as fruit, vegetables and/or mineral
water; normal haematological and biological status; physical
activity between 1·25 and 3·75 according to the question-
naire-based index established by Baecke et al. (36); negative
HIV and hepatitis C virus tests; signed inform consent. The
ethical committee of the Auvergne region (France) approved
the protocol.
Milk content
The ultra-heat-treated semi-skimmed milk used in the
present study contained per 250 ml: 300 mg calcium, 481 kJ
(115 kcal), 8 g proteins, 4 g lipids, 11·5 g glucides, no vitamin D.
Study design
At the beginning of the study an oral dose of 100 000 IU
vitamin D3 contained in a 2 ml vial (Uve´dose
w, Laboratoire
Crinex, France) was taken by all participants. This adminis-
tration was aimed at avoiding any vitamin D insufficiency
during the experimental phase. Then, a 4-week period of
adaptation was started with diet providing 600 mg calcium
plus 300 mg provided by 250 ml semi-skimmed milk. Then
during the next 6 weeks the participants were maintained
under the same 600 mg calcium diet and randomized to
receive either a supplement of 500 ml semi-skimmed milk,
thus providing a total of 1200 mg calcium, or no milk
supplement. In a third phase of 6 weeks they were switched
to the alternative regimen (Fig. 1). The participants were
free to consume the milk supplement at one time or in seve-
ral portions during the day. During the last 24 h of the adap-
tation phase and of each experimental period, i.e. after 4, 10
and 16 weeks, the participants were asked to collect their
urine. The next morning after voiding the overnight urine,
samples of both urine and blood were collected in the fast-
ing state.
Food control. During the 16 weeks of the study, the vol-
unteers had to limit their calcium intake to 600 mg/d. For
this purpose, the certified dietitian (M. B.-B.) of the investi-
gating team provided the volunteers with a list of foods not
to be consumed because of their high calcium content, as
well as a list of dairy products they had to eat daily in
precise amounts. Water bottles with very low mineral con-
tent were distributed to substitute for more mineralized
drinking water.
The nutrient intake was assessed at four occasions: at the
time of inclusion into the study; by the end of the adaptation
period; by the end of the 6-week period without milk
supplementation; by the end of the 6-week period with milk
supplementation. Each assessment was made by using the
diary method over 7 d, with weighing by the participants of
all consumed foods. Furthermore, the recorded dietary data
in the diary was validated by an interview of the participants
by the certified dietitian involved in the study (M. B.-B.).
The food nutrient content was obtained by computer analysis
using the software Geni version 6.0 (Micro6w, Villers les
Nancy, France). This software is based on the pre-recorded
nutrient table from Re´pertoire Ge´ne´ral des Aliments (37).
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No instruction aimed at reducing spontaneous intake to avoid
weight gain was given to the participants.
The compliance was assessed by both interviewing the par-
ticipants at the time of checking the data recorded in their
diary and by counting the milk bottles which were not consumed.
Biochemical measurements
As previously reported(38), calcium and magnesium were
measured by colorimetry, sodium and potassium by indirect
potentiometry with the use of specific electrodes, and creati-
nine by the Jaffe reaction (Roche Diagnostics, Meylan,
France). Serum parathyroid hormone (PTH), osteocalcin,
amino-terminal propeptide of type I procollagen (PINP) and
carboxy terminal crosslinked telopeptide of type I collagen
(CTX; Cross-laps) were measured by automated immuno-
chemiluminescence on the Elecsys platform (Roche Diagnos-
tics) as recently described(39). For these four biochemical
analyses the within- and between-run CV were lower than
5 %, whatever the concentration tested. The reference range
of these assays was established in a group of fifty-nine pre-
menopausal healthy women aged 35–48 years. All of them
had regular menses associated with plasma follicle-stimula-
ting hormone concentration below 12 mU/l. They received a
single dose of 100 000 IU vitamin D3 1 week before the
blood sampling. The reference ranges were 10–46 pg/ml,
13–32 ng/ml, 19–50 ng/ml and 700–3000 pmol/l for PTH,
osteocalcin, PINP and C-telopeptide, respectively. Bone
alkaline phosphatase (BAP) was measured by automated
immunochemiluminescence on the Access II platform (Beck-
man-Coulter, Chaska, MN, USA). BAP within-run CV was
6·7 % at mean concentration of 13·2mg/l and below 5 % at
concentration above 25mg/l. The reference range established
in healthy premenopausal women was 4–15mg/l. The serum
level of 25-hydroxyvitamin D was measured by RIA
(DiaSorin, Stillwater, MN, USA) as previously reported(40).
Vitamin D insufficiency was defined as a serum level of
25-hydroxyvitamin D lower than 30 ng/l(41). Serum insulin-
like growth factor (IGF) I was measured by an immunoradio-
metric assay (IGF-I RIA-CT; Schering-Cis Bio, Gif sur
Yvette, France) based on the use of two monoclonal anti-
bodies directed toward different IGF I epitopes. In this
method, bound IGF I is displaced from IGF binding protein
by acidification. A large excess of IGF II is then added to
the acid-treated serum to prevent reassociation of IGF I
with its carrier proteins when buffer is added. The analytical
properties of this assay were recently reported(39). The
normal range of serum IGF I in women aged 36–65 years
was 77–247 ng/ml.
Indices of the renal reabsorption of either calcium (TRCaI,
mmol/l glomerular filtration rate) or inorganic phosphate
(TmPi/l, glomerular filtration rate) were calculated as previously
described(42,43) from calcium, inorganic phosphate and creati-
nine determinations in the plasma and urine samples collected
in the fasting state at the end of the intervention periods. Like-
wise, the estimation of the net release of calcium from bone
(BRI, mmol/mmol) was calculated from the ratio of calcium
over creatinine urine concentration(43,44). These three indices
allow one to discriminate disturbances in calcium–phosphate
metabolism that occur in various benign and malign hypercal-
caemic diseases(43,44).
Dual X-ray densitometry
aBMD of the lumbar spine (L2–L4) and femoral neck were
measured by dual X-ray absorptiometry on a Hologic QDR
4500 osteodensitometer (Hologic, Massy, France). The deter-
minations were made 3–5 weeks before the enrolment in
order to exclude women with osteoporosis, i.e. with T-score
# 22·5 according to the WHO definition(35). The reference
range used to calculate T-score values was that provided by
the osteodensitometer manufacturer.
Fig. 1. Experimental protocol: the crossover design was applied to thirty postmenopausal women randomized in two groups (Gr) either with or without milk sup-
plementation (suppl.) during two periods of 6 weeks that were preceded by an adaptation period of 4 weeks. , Blood and urine samples were collected at the end
of the adaptation phase and at the end of each of the two experimental periods.
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Statistical analysis
The statistical power was deduced from the expected change in
serum CTX that was a priori considered as the main end-point of
the study. By using a crossover design, it was expected that a
difference would be detected in serum CTX between periods
with and without milk supplementation by 20 % with a power
of 80 % and a two-sided a of 0·05. Taking into account a
measured intra-individual CV of 10 %, the 20 % difference in
serum CTX required a sample of twenty subjects in a cross-
over-designed study. Thirty subjects were eventually enrolled
in order to secure a greater power to the study.
The results are expressed as means and standard deviations
in all tables and means and their standard errors in the figure
depicting the average of individual differences as expressed in
percentage change between the two experimental periods.
Paired Student’s t test was employed to assess differences
between the two periods. Bonferroni’s correction was used
for the four-biochemical bone remodelling variables, i.e.
CTX, PINP, osteocalcin and BAP. P#0·05 was considered
statistically significant.
Results
Baseline characteristics
None of the thirty enrolled women dropped out of the study.
They had passed menopause for approximately 9 years
(Table 1). Their anthropometric variables (standing height,
body weight and BMI) were within the normal range determined
in the French women population for that age (Table 1). The oes-
trogen-deficient status was expressed by the elevation of plasma
follicle-stimulating hormone. As expected in non-oestrogen-
substituted women at about 9 years from menopause, the
osteodensitometric mean T-score values were in the low
normal and slightly osteopaenic ranges for the femoral neck
and lumbar spine, respectively (Table 1). The blood biochemical
markers CTX, PINP, osteocalcin and BAP reflected on the
average an increase in bone remodelling as compared to the pre-
menopausal normal ranges (Table 2). All subjects had a serum
level of 25-hydroxyvitamin D .20 ng/ml. The mean value of
serum PTH was within the normal range (Table 2).
Dietary changes during intervention
The semi-skimmed milk supplementation resulted in an
increase in energy intake that was associated with a significant
increase of 16 % in total protein intake as well as in the per-
centage of protein per energy intake (Table 3). Neither the
carbohydrate nor lipid density were significantly altered by
the semi-skimmed milk supplementation (Table 3). Calcium,
inorganic phosphate, potassium and magnesium intakes sig-
nificantly increased by 93, 38, 25 and 13 %, respectively,
while sodium intake remained virtually constant during the
two experimental periods of 6 weeks (Table 3).
Body weight and consequently BMI were not influenced by
the semi-skimmed milk supplementation. In this regard, the
500 ml milk/d provided an additional intake of 962 kJ
(230 kcal), 16 g proteins, 8 g lipids and 23 g glucides. The
data recorded in the dietary diary indicates, as compared to
the period without milk, a daily increase of 339 kJ (81 kcal),
10·6 g proteins, 0·1 g lipids, 10·5 g glucides. Thus, on the ave-
rage, the participants reduced their spontaneous intake by
623 kJ (962 to 339 kJ; i.e. by 149 kcal (230 to 81 kcal)),
5·4 g proteins (16·0 to 10·6 g), 8 g lipids and 12·5 g glucides
(23·0 to 10·5 g). This reduction and consequently mild increase
in daily energy intake (less than 5 %) can explain why we
were unable to detect a significant gain in body weight by
the end of the period of milk supplementation.
Biochemical changes during intervention
Several variables related to bone metabolism were signifi-
cantly influenced by the milk supplementation with a
reduction in blood PTH, CTX, PINP and osteocalcin
(Table 4). Neither BAP nor IGF I was statistically altered
(Table 4). Figure 2 illustrates the percentage difference
between the two experimental periods of these six blood vari-
ables. An additional statistical analysis by both paired t test
and ANOVA for repeated measurements was made in order
to test whether the order of the intervention may have influ-
enced the results. This analysis did not provide evidence
that the significant decrease observed in the whole cohort
(groups A þ B) for PTH, CTX, PINP and osteocalcin was
influenced by the order of the 6-week intervention periods,
with milk supplementation during the first and second period
in group A and B, respectively (data not shown).
Of note is that the mean absolute values of PTH, CTX, PINP
and osteocalcin by the end of the adaptation period during
Table 1. Baseline characteristics of the thirty postmenopausal women
(Mean values and standard deviations)
Mean SD
Age (years) 59·5 3·3
Years since menopause (years) 9·2 3·2
Standing height (cm) 162·4 6·8
Body weight (kg) 62·1 7·5
BMI (kg/m2) 23·7 3·4
Plasma FSH (IU/l) 95·8 26·0
Lumbar spine aBMD (T-score) 21·10 0·98
Femoral neck aBMD (T-score) 20·88 0·71
Physical activity (score) 2·63 0·58
aBMD, areal bone mineral density; FSH, follicle-stimulating hormone.
Table 2. Blood biochemical variables determined at the end of the
4-week adaptation period*
(Mean values and standard deviations)
Mean SD
Calcium (mmol/l) 2·47 0·07
Inorganic phosphate (mmol/l) 1·18 0·12
Creatinine (mmol/l) 66·9 6·6
25-Hydroxyvitamin D (ng/ml) 33·8 4·4
PTH (pg/ml) 40·4 10·5
CTX (pmol/l) 4207 1848
PINP (ng/ml) 62·7 26·1
Osteocalcin (ng/ml) 30·9 12·0
Bone alkaline phosphatase (mg/ml) 12·0 4·1
IGF I (ng/ml) 153·3 48·2
CTX, crosslinked telopeptide of type I collagen; IGF, insulin-like growth factor;
PINP, propeptide of type I procollagen; PTH, parathyroid hormone.
* For details of procedures, see Materials and methods.
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which the subjects consumed 250 ml milk/d were intermediary
(Table 2) between those recorded by the end of the period with-
out and with a milk supplementatin of 500 ml/d (Table 4).
Among the urinary variables, the 24 h urine excretion was
significantly elevated for inorganic phosphate (þ3·3 mmol/d,
P¼0·019) and potassium (þ12·1 mmol/d, P¼0·0109), but
not for calcium (þ0·14, P¼0·633) during the milk-sup-
plemented period. Neither TRCaI nor TmPi was significantly
modified by the intervention, nor BRI (Table 5).
Discussion
There has been a renewed interest in non-pharmacological rec-
ommendation for attenuating bone loss in postmenopausal
women. This stems from doubt raised by results obtained in
large studies about adverse effects of hormonal replacement
therapy with increased risk of CVD and breast cancer(12). Fur-
thermore, none of the other pharmacological agents such as
bisphosphonates, the selective oestrogens receptor modulator
raloxifene, strontium ranelate and PTH is recommended by
national and international drug regulatory authorities to be
used in the primary prevention of postmenopausal osteoporo-
sis; their use in primary prevention being limited to women at
high risk of experiencing, in a relatively short time, fragility
fractures. For these various reasons only supplements of
calcium and vitamin D are often prescribed. However, their
efficacy is limited, particularly because of the difficulty in
maintaining a satisfactory compliance in postmenopausal
women not at increased risk of osteoporosis(22).
The present study indicates that milk supplementation given
to postmenopausal women with mean age slightly below
60 years and aBMD values either normal in the femoral
neck (T-score 20·88) or at the upper limit of the osteopaenic
range in the spine (T-score 21·10)(35) results in bone
remodelling inhibition. Without milk supplementation the aver-
age of the serum bone resorption marker CTX was above the pre-
menopausal reference values. With milk supplementation, the
14 % fall in serum CTX was not only statistically significant
Table 3. Nutritional variables during the period without and with milk supplementation*
(Mean values and standard deviations)
Period without milk
supplementation
Period with milk
supplementation
Mean SD Mean SD Difference P †
Energy (kJ/d) 7088 1172 7427 1506 þ339 NS
Energy (kcal/d) 1694 280 1775 360 þ81 NS
Protein (g/d) 68·3 14·9 78·9 16·5 þ10·6 ,0·0001
Protein (% energy) 16·7 2·9 18·5 3·1 þ1·8 0·0011
Carbohydrates (% energy) 46·3 7·0 46·5 6·3 þ0·17 NS
Lipids (% energy) 37·0 6·0 35·0 5·3 21·95 NS
Calcium (mg/d) 572 107 1105 143 þ533 ,0·0001
Phosphorus (mg/d) 920 173 1272 230 þ352 ,0·0001
Sodium (mg/d) 2147 645 2158 474 þ11 NS
Potassium (mg/d) 2560 567 3200 552 þ567 ,0·0001
Magnesium (mg/d) 234 56 264 52 þ31 0·0025
* For details of procedures, see Materials and methods.
†P values are computed by paired t test between the period with and without milk supplementation.
Table 4. Blood biochemical variables determined at the end of the 6-week period without and with milk supplementation*
(Mean values and standard deviations)
Period without milk
supplementation
Period with milk
supplementation
Mean SD Mean SD Difference P †
Calcium (mmol/l) 2·32 0·08 2·32 0·11 0 –
Inorganic phosphate (mmol/l) 1·25 0·14 1·22 0·15 20·03 NS
Creatinine (mmol/l) 66·6 7·6 67·2 7·3 þ0·6 NS
Proteins (g/l) 68·3 3·5 69·8 3·1 þ1·5 NS
Albumin (g/l) 39·1 2·1 39·9 2·3 þ0·8 NS
25-Hydroxyvitamin D (ng/ml) 29·0 4·7 28·8 5·1 20·2 NS
PTH (pg/ml) 43·0 10·8 39·8 10·8 23·2 0·0054
CTX (pmol/l) 4445 1909 3821 1749 2624 0·0001
PINP (ng/ml) 64·9 24·3 59·5 21·8 25·5 0·0092
Osteocalcin (ng/ml) 31·5 13·2 28·7 10·6 22·8 0·0014
Bone alkaline phosphatase (mg/ml) 12·2 3·6 12·2 3·7 0 –
IGF I (ng/ml) 157·3 40·2 164·0 42·5 þ6·7 NS
CTX, crosslinked telopeptide of type I collagen; IGF, insulin-like growth factor; PINP, propeptide of type I procollagen; PTH, parathyroid hormone.
* For details of procedures, see Materials and methods.
†P values are computed by paired t test between the period with and without milk supplementation.
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but also appears to be biologically meaningful. Indeed, the
mean absolute value of serum CTX was close to the upper
limit of the reference range established from blood samples
of healthy premenopausal women as determined in the same
laboratory by one co-investigator of the present trial (J.-C. S.).
Other markers of bone remodelling that reflect bone for-
mation such as PINP and osteocalcin fell significantly but
somewhat less than the marker of bone resorption, while no
variation was observed in serum BAP. Osteocalcin, PINP
and BAP reflect different stages of the osteoblastogenesis,
i.e. the phases of proliferation, matrix maturation and mineral-
ization. The reason why BAP was not affected in contrast to
previous studies with milk(45) or high calcium mineral
water(46) supplementation does not appear to be due to the
cross-over study design. Indeed, BAP was not influenced
whether milk supplemention was given during the first
(group A) or the second (group B) period of 6 weeks.
Interestingly enough, the data are compatible with a milk
dose response since the mean values of PTH, CTX, PINP
and osteocalcin fell progressively down from no supplemen-
tation to 250 and 500 ml/d (Tables 2 and 4).
The pattern of biochemical markers of bone remodelling we
observed recalls that recorded during the early phase of inter-
ventions using pharmaceutical anti-resorbing agents, such as
oestrogens, bisphosphonate or raloxifene. It suggests that the
foregoing reported milk intervention positively uncoupled
the two processes of bone remodelling.
Overall, the present results are consistent with reported effects
of calcium supplementation, taken either as isolated calcium
salts, mineral water(24,33,47,48) or milk(45,49), on bone remodel-
ling markers of postmenopausal women. However, these trials
were conducted in cohorts including, at least in part, older
postmenopausal women who were therefore at higher risk of
osteoporosis(24,33,47,48). Indeed, besides the decline in aBMD,
advancing age is an additional independent factor increasing
the risk of fragility fractures(35). Thus, for a given T-score of
21·0, the estimated 10-year risk for experiencing a fragility
fracture is twice as high at 70–75 than at 50–55 years of
age(50). Therefore, in the clinical setting, the decision for pre-
scribing pharmaceutical agents(4,51) should be determined not
only by the osteodensitometry value(52) but also by the identifi-
cation of risk factors among which age(35), previous fracture(53)
and BMI(3) have been clearly identified as of substantial impor-
tance in large-scale epidemiological studies.
The present study indicates that in relatively early postmeno-
pausal years milk supplementation can efficiently slow down the
rate of bone remodelling. The present observation sustains the
notion that in postmenopausal women with femoral neck and
lumbar spine aBMD values still within the normal range or in
the upper part of the osteopaenic/low bone mass range(35), and
without any major detectable risk factor, preventive measures
for bone loss resulting from oestrogen deficiency should
be centred on lifestyle factors(54). The present study brings
biochemical support to this notion that is recommended by seve-
ral national and international health institutions.
The inhibition of biochemical markers of bone remodelling
probably resulted from the observed concomitant reduction in
the serum level of PTH which, in turn, was probably mediated
by the increased calcium intake. In addition, the milk-induced
increment in protein intake may also have contributed to the
reduction in the circulating level of PTH. Indeed, it has been
Fig. 2. Differences in percentage between the period without and with milk
supplementation. Values are means with their standard errors depicted by
vertical bars. Mean values were significantly different from zero: *P¼0·0054,
0·0010, 0·0092, 0·0014, for parathyroid hormone (PTH); crosslinked telopep-
tide of type I collagen (CTX), propeptide of type I procollagen (PINP) and
osteocalcin (OC), respectively. The corresponding absolute values are
presented in Table 4. BAP, bone alkaline phosphatase; IGF, insulin-like
growth factor.
Table 5. Calcium and inorganic phosphate fluxes, and urinary electrolyte excretion*
(Mean values and standard deviations)
Period without milk
supplementation
Period with milk
supplementation
Mean SD Mean SD Difference P †
Urine calcium (mmol/24 h) 4·0 1·9 4·1 2·0 þ0·1 NS
Urine inorganic phosphate (mmol/24 h) 24·4 7·7 27·8 7·0 þ3·3 0·0195
TRCaI (mmol/l GFR) 2·64 0·15 2·62 0·14 20·02 NS
TmPi (mmol/l GFR) 1·21 0·17 1·19 0·23 20·02 NS
BRI (mmol Ca/mmol creatinine) 0·29 0·16 0·30 0·16 þ0·01 NS
Urine sodium (mmol/24 h) 122·6 39·7 122·0 47·0 20·6 NS
Urine potassium (mmol/24 h) 60·5 18·4 72·7 23·2 þ12·1 0·011
BRI, net calcium bone resorption index; GFR, glomerular filtration rate; TmPi, tubular inorganic phosphate reabsorption capacity; TRCaI, renal tubular calcium reabsorption index.
* For details of procedures, see Materials and methods.
†P values are computed by paired t test between the period with and without milk supplementation.
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demonstrated that independently of any change in calcium con-
sumption, increasing protein intake enhances intestinal calcium
absorption capacity while reducing the serum level of PTH(55).
This effect could explain the fact that increasing both calcium
and protein intakes can exert a positive impact on bone integrity.
Furthermore, data suggest that these two nutrients may synergis-
tically interact on calcium economy and bone metabolism(56–58).
In keeping with this notion, a positive effect of milk basic protein
on lumbar spine aBMD of healthy postmenopausal women
was associated with a reduction in urinary bone resorption
marker without concomitant decrease in serum osteocalcin(59).
All enrolled subjects remained compliant to the prescribed
milk consumption. This maximal degree of both adherence
and persistence during the 6-week period of milk supplemen-
tation reflects the good acceptability of this dairy product in
this cohort of early postmenopausal women.
Several limitations of the reported trial have to be mentioned.
A first limitation is the short time length of the study. It remains
uncertain that both the reduced PTH level and bone turnover rate
with greater inhibition in markers of bone resorption than
formation will be maintained in the long term, eventually resul-
ting in a substantial bone loss attenuation.
Second, the magnitude of the reduction in markers of bone
resorption at the end of the milk supplementation was less
than with therapeutic doses of strong inhibitors of bone resor-
ption such as bisphosphonates(1,60). However, it was close to
that observed during the first months following the intervention
onset with other inhibitors of bone resorption, such as low doses
of oestrogens, raloxifene or strontium ranelate(61 – 63). Neverthe-
less, with these compounds the reduced risk of experiencing new
vertebral fractures(12,64,65) was similar to that recorded under
therapy with bisphosphonates such as alendronate or risedro-
nate(65,66).
Third, the good tolerability to the supplementation observed
in the present cohort can be due in part to a biased selection of
enrolled subjects who were volunteers for the study and there-
fore had no particular dislike for milk. Therefore, one may
expect a reduced percentage of postmenopausal women
ready to step in and then to adhere and persist to drink daily
half a litre of semi-skimmed milk. Nevertheless, more varying
regimens providing an equivalent amount of calcium and pro-
teins obtained from other dairy products could exert a similar
positive impact on bone metabolism.
Conclusion
A 6-week period of milk supplementation leading to a mean
increase in calcium intake from 572 to 1105 mg/d and of
protein intake from 68 to 79 g/d induced a significant decrease
in several biochemical variables, a response compatible with a
reduction of bone turnover. This nutritional approach, meant
to alleviate the acceleration in bone remodelling, may be a
valuable alternative to pharmaceutical therapy in postmeno-
pausal women not at increased risk of osteoporosis.
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